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E-mail address: tcchang@ndmctsgh.edu.tw (T.-C. CRecent studies indicated that the RIG1 (RARRES3/TIG3) plays an important role in cell proliferation,
differentiation, and apoptosis. However, the regulatory mechanism of RIG1 gene expression has not
been clearly elucidated. In this study, we identiﬁed a functional p53 response element (p53RE) in the
RIG1 gene promoter. Transfection studies revealed that the RIG1 promoter activity was greatly
enhanced by wild type but not mutated p53 protein. Sequence speciﬁc mutation of the p53RE abol-
ished p53-mediated transactivation. Speciﬁc binding of p53 protein to the rig-p53RE was demon-
strated using electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation
(ChIP) assay. Further studies conﬁrmed that the expression of RIG1 mRNA and protein is enhanced
through increased p53 protein in HepG2 or in H24-H1299 cells. In conclusion, our results indicated
that RIG1 gene is a downstream target of p53 in cancer cell lines.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
RIG1 (retinoid-inducible gene 1), also named as tazarotene-in-
duced gene 3 (TIG3) or retinoic acid receptor responder 3 (RAR-
RES3), is identiﬁed as a retinoid-induced gene [1,2]. The RIG1
belongs to H-rev107 family of class II tumor suppressor genes
[3]. A special feature of class II tumor suppressor inactivation is
its reversibility triggered by various agents, which is different from
class I tumor suppressor genes that have sustained mutations in
cancer [4]. The H-rev107 family of proteins functions to inhibit cell
proliferation and their expression is associated with suppression of
transformed phenotype [5]. Evidences have accumulated in that
RIG1 may be a growth regulator that mediates the growth suppres-
sive effects of retinoids. For example, decreased cell proliferation
was shown with RIG1 overexpression in different human cells
[1,6]. Studies indicated that overexpression of RIG1 suppressed
the colonies formation in T47D and HaCaT cells [1,6]. Compare to
normal cells, the expression of RIG1 was decreased in many human
cancer specimens [7–9]. RIG1 has also been shown to facilitatechemical Societies. Published by E
ochemistry, National Defense
OC. Fax: +886 2 87923106.
hang).apoptosis and the terminal stages in keratinocyte differentiation
via activation of type I transglutaminase [6].
Considering the connection of RIG1 with cell proliferation,
tumorigenesis, and apoptosis, the regulatory mechanism of RIG1
expression merits further investigation. In our previous study, a
DR5 (direct repeats separated by ﬁve nucleotides)-containing ac-
tive promoter fragment (5403/5046 relative to the translation
starting site) was identiﬁed to be the main mediator of all-trans
retinoic acid (atRA) responsiveness of this gene [10]. Sequence
analysis of this fragment revealed a notable p53 response element
(p53RE, 5157/5134) located 85 bp downstream from the func-
tional DR5 element is identiﬁed. The presence of p53RE suggests
that RIG1 gene might be a direct transcriptional target of the class
I tumor suppressor p53. In fact, impairment of p53 can cause a
diminished expression of a number of class II genes [11–13]. For
example, wild-type p53 stimulates the expression of the class II
tumor suppressors such as the signaling regulator caveolin-1
[11], the serine protease inhibitor maspin [12], p33 (ING1, and
inhibitor of growth-1) [13]. p53 protein is the cellular keeper for
growth and division, which plays an important role in preventing
malignant progression [14]. Consequently, the tumor suppressor
gene p53 has been found to be commonly mutated in various
human tumors, as about half of all human tumors producelsevier B.V. All rights reserved.
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sponse to cellular stresses including DNA damage, hypoxia, and a
variety of abnormal proliferative signals. The major mechanism
by which p53 confers its cellular activities is by transcriptional
activation of speciﬁc target genes. p53 binds as a homotetramer
to p53RE found in promoter or enhancer of its target genes. The
consensus p53RE generally consists of two tandem repeats of the
10-bp motif, 50-PuPuPuC(A/T)(T/A)GPyPyPy-30, separated by 0–
13 bp [15]. The DNA-binding activity is essential for p53 to func-
tion as a tumor suppressor. In fact, the expression of many p53 tar-
get genes was shown to be the downstream mediator of a broad
spectrum of p53 responses in various types of cellular stress. These
genes include p21, MDM2, BAX, noxa, puma, insulin-like growth
factor-binding protein 3 gene (IGF-BP3), cyclin G1, Gadd45, and
many others [14,16]. The p53 protein has also been shown to re-
press transcription of a number of cellular gene, such as RB, c-
fos, and DNA topoisomerase IIa [17]. Despite that many p53 re-
sponse genes were identiﬁed over these years, it is believed that
there are still unidentiﬁed p53 target genes in human genome [18].
Since the RIG1 belongs to a class II tumor suppressor gene and
because of the presence of a putative p53RE in its upstream regu-
latory region, it is interesting to investigate whether RIG1 gene is a
downstream target of p53 protein. Here, we present evidence to
demonstrate that the RIG1 gene contains a functional p53RE and
is a transcriptional target of p53 protein in cancer cell lines.
2. Materials and methods
In this study, the wt-p53 expressing HepG2 cells, the p53-null
Hep3B cells, and the human lung cancer H24-H1299 cells, a p53-
null H1299-derived cell line with a Tet-off controlled expression
of wt-p53 were used. Additional information on oligonucleotides,
plasmid construction, and methodological details are available in
Supplementary data.
3. Results
3.1. p53 induces expression of endogenous RIG1 in human cancer cells
Previous study from our laboratory demonstrated the presence
of a DR5 RA response element (RARE) in the upstream genomic re-
gion of RIG1 gene [10]. A p53RE at 5157, and many other se-
quence motifs, clustered along with the DR5 element that forms
the primary active regulatory fragment of RIG1 promoter [10]. This
is the only p53RE found in the RIG1 genomic region up to -15000
relative to the translational starting site analyzed using the GCG
software. As shown in Fig. 1A, the sequence element consists of
two tandem repeat palindromic binding sites with homology to
the consensus p53RE separated by 4 bp. As we are elucidating
the functional role of RIG1 gene, it was of particular interest to
determine whether the RIG1 gene is a transcriptional target of
p53. To conﬁrm the ability of p53 in the induction the RIG1 expres-
sion in human cancer cells, the RIG1 mRNA or protein levels in re-
sponse to p53-inducing stimuli, such as 5-FU and UV irradiation, in
HepG2 cells were analyzed. The expression of p21 was also exam-
ined as a positive control of the p53-upregulated genes. As shown
in Fig. 1B, along with increasing p53 level, RIG1 protein level was
induced to 2.42- and 3.41-fold in cells treated with 5-FU or UVB,
respectively. As a control, these extracellular stimuli fail to confer
induction on RIG1 protein and mRNA level in the p53-null Hep3B
cells (Fig. 1B and S1).
The effect of 5-FU on induction of the RIG1 mRNA was also
examined. Results in Fig. 1C showed that the RIG1 mRNA level
was induced to about 6-fold in the presence of 5-FU in a time-
and dose-dependent manner. Induction of the RIG1 expression
was also investigated using the H24-H1299 cells in which p53proteins was induced upon withdrawal of tetracycline. Results
shown in Fig. 1D demonstrated that, upon withdrawing of tetracy-
cline for 48 h, the RIG1 protein increased up to 2.78-fold which
correlates well with the induction of p53 protein. These results
demonstrated that p53 up-regulates the expression of RIG1.
3.2. p53 activates the RIG1 promoter in a dose-dependent manner
In order to investigate whether activation of RIG1 promoter is
dependent on p53 protein, RIG1 promoter luciferase construct
Rig-2228, that displayed potent promoter activity shown in our
previous study [10], was transfected into human hepatic HepG2
cells, or Hep3B cells. The cells were cotransfected or treated with
increasing concentration of the wild type p53 expressing plasmid,
pCMV-p53, or 5-FU, respectively. The cells were then harvested
and analyzed for p53 protein level and luciferase activity. Results
shown in Fig. 2A demonstrated that increased p53 protein expres-
sion was observed in both cell lines cotransfected with pCMV-p53
plasmid. As expected, there was a clear increase in p53 expression
only in the 5-FU-treated HepG2 cells. Results shown in Fig. 2B
demonstrated that the p53-mediated induction of RIG1 promoter
activity correlated well with increasing 5-FU concentration in
HepG2 cells. In addition, cotranfection of the pCMV-p53 plasmid
induced p53-mediated response in a dose–response manner. The
p53-dependent activation of RIG1 promoter reporters was also ob-
served in several other human lines (Data not shown). These re-
sults demonstrated that the activation of RIG1 gene promoter is
dependent on the presence of p53 protein.
3.3. The rig-p53RE is required for p53-mediated induction
To verify the presence of a functional p53RE in the RIG1 pro-
moter region, the RIG1 promoter fragments with or without the
putative p53RE at nucleotides 5157/5134 were constructed,
as described in Fig. 3A. Promoter constructs were transiently trans-
fected into HepG2 cells and Hep3B cells with or without 5-FU or
the p53 expression plasmid pCMV-p53. The p21-Luciferase repor-
ter was served as a positive control for p53-mediated activation.
The RIG1 promoter fragments containing the putative rig-p53RE
displayed 3- to 10-fold increase in luciferase activity when p53
was present in these cells (constructs Rig0705 and Rig2228 in
the Fig. 3B). As expected, 5-FU induced rig-p53RE activation only
in HepG2 cells. Deletion of the putative rig-p53RE (construct
Rig2136) completely abrogated the effect of p53. To verify that
the positive effect of p53 is mediated by the p53RE identiﬁed in
the RIG1 gene, we mutated nucleotides within this element that
are known to be necessary for direct binding of p53 (construct
Rig-m2228). As shown in Fig. 3B, mutation of the rig-p53RE abol-
ished the 5-FU or p53-dependent activation. These observations
imply that p53 responsiveness of the reporter plasmids is indeed
due to the presence of the putative rig-p53RE identiﬁed in the
RIG1 upstream genomic region. Our observations demonstrated
that the p53RE in RIG1 gene promoter is well functional and efﬁ-
ciently confers RIG1 gene expression in human cancer cells in re-
sponse to p53 protein.
3.4. The rig-p53RE binds p53 protein
Sequence-speciﬁc DNA binding activity of p53 is important be-
cause it is indispensable for the transcriptional activity of the pro-
tein. In order to testify that p53 is a transcription factor of RIG1
promoter, DNA binding assay was performed. RIG1 promoter frag-
ments with or without the p53RE were prepared by PCR and the
fragment rig 5175/5129 was radiolabeled (Fig. 4A). The labeled
probe was incubated with nuclear extracts prepared from 5-
FU treated HepG2 cells. The p53-speciﬁc monoclonal antibody


































Fig. 1. RIG1 is a potential p53 target gene. (A) Sequence and localization of p53RE in the RIG1 gene promoter. The localization of the indicated sequence motifs is labeled
relative to the translational starting site. Bold letters indicate the positions of the core palindromic p53 binding sites within each decamer. (B) Effect of DNA damaging agents
on expression of p53 and RIG1. Human hepatic HepG2 cells (left panel) or Hep3B cells (right panel) were untreated or treated with UVB (100 mJ/cm2), 10 lg/mL 5-FU or TCDD
(109 M) for 48 h, and immunoblotting was carried out. (C) Effect of 5-FU on expression of the RIG mRNA. Human HepG2 cells were incubated with the indicated
concentrations of 5-FU (0–25 lg) or 10 lg/mL 5-FU for varying periods of time and then analyzed by qRT-PCR. (D) Effect of p53 overexpression on RIG1 induction. H24-H1299
cells were incubated for the indicated times in the absence (p53 induced) or presence of tetracycline (2 mg/mL, control).
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Fig. 2. p53 activates RIG1 promoter in a dose-dependent manner. (A) Effect of 5-FU or pCMV-p53 on intracellular p53 protein level in human cells. Cells were treated with 5-
FU (10 lg/mL) or transfected with pCMV-p53 plasmid (0.5 lg) for 48 h. Whole cell extract (30 lg) were analyzed by immunoblotting for p53 level. (B) p53-dependent
activation of Rig2228-luciferase reporter (Fig. 3A) in different cells. The cells were transfected and treated with increasing concentrations of 5-FU or cotransfected with
pCMV-p53 plasmid for 48 h. The pCMVP vector encoding the P-galactosidase gene was used as an internal control. Luciferase activity in the presence of 5-FU or p53 was
normalized for the activity in the absence of 5-FU or p53, respectively, to obtain a fold of activation. Results shown represent mean ± SD (n = 6).
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formation of p53-DNA complexes by imparting a conformational
change in p53, as previously reported [19]. Results shown in
Fig. 4B demonstrated the speciﬁc complex formation between
the rig-p53RE and p53 protein (lane 2, Fig. 4B). Binding speciﬁcity
was veriﬁed by competition with an excess of unlabeled DNA
probe (rig 5175/5129, lanes 3 and 4 of Fig. 4B), or promoter
fragments containing the rig-p53RE (rig 5175/5086, lanes 9
and 10 of Fig. 4B) or p21-p53RE (lane 11 of Fig. 4B). On the con-
trary, no competition was observed for promoter fragments with-
out rig-p53RE (rig 5128/5086 and 5175/5159, lanes 5–8 of
Fig. 4B) or with mutated rig-p53RE (rig-mp53RE, lane 12 of
Fig. 4B). As a binding control for p53 protein, similar studies were
carried out using the p53RE of p21 promoter as labeled probe and
competed with the RIG1 promoter fragments. Results shown in
Fig. 4C demonstrated that rig-p53RE containing fragments, rig
5175/5129 and rig 5175/5086, effectively competed for
the complex formation (lanes 15 and 18) and there is no competi-
tion from DNA fragments without p53RE (lanes 16 and 17). In
addition, there is no complex formation when rig-mp53RE was
used as labeled probe (Fig. 4C, lanes 19 and 20). These results indi-
cated that the rig-p53RE functions efﬁciently as a p53 binding site
to regulate RIG1 gene expression.
To determine whether p53 is associated with RIG1 promoter
in vivo, ChIP assay was performed. Results shown in Fig. 4D dem-onstrated that p53 binding to the chromatin was greatly enhanced
in HepG2 cells treated with 5-FU. Similar ChIP assay results were
also observed in H24-H1299 cells, the p53 binding to RIG1 pro-
moter chromatin is markedly increased in cells with tetracycline
withdrew (Fig. 4E). Taken together, these results demonstrated
that p53 could bind directly in vitro and in vivo to its corresponding
binding sites in the RIG1 promoter region.
4. Discussion
In this study, the involvement of p53 in RIG1 gene expression
was investigated. We found that the RIG1 promoter activity was
greatly enhanced by cotransfection with wild type p53 expres-
sion vector. Moreover, the extent of activation of the RIG1 pro-
moter was apparently p53-dose-dependent. Mutation at the
sequence of the rig-p53RE completely blocked p53-mediated
enhancement. In addition, the RIG1 promoter was induced by
5-FU only in wt-p53-expressing HepG2 cells but not in p53-null
cells (Figs. 2 and 3). The fold of induction in HepG2 is constantly
lower than that in Hep3B cells. This may be due to the higher
basal levels of reporter activity induced by constitutively
expressed wt-p53 in HepG2 cells, which lowered the fold of
induction induced by exogenous p53. From these studies, we
veriﬁed the functionality of rig-p53RE in transactivation of RIG1
gene in human cells.
Fig. 3. p53RE is crucial for the full activities of RIG1 promoter. (A) The RIG1 promoter constructs used in this study [10]. Nucleotide sequences of wild type and mutated p53RE
(rig-p53RE and rig-mp53RE, respectively) are shown and the mutated nucleotides are underlined and labeled in bold letters. (B)Transcriptional activity of the RIG1 genomic
constructs in different cells. The transfected cells were treated in the absence or presence of 5-FU (10 lg/mL) or cotransfected with pCMV-p53 plasmid (0.5 lg) for 48 h before
harvested for analysis.
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sites separated by 4-bp with some mismatches in the ﬁrst half site
(Fig. 1). This site exhibited, both in vivo and in vitro, speciﬁc binding
afﬁnity to p53 which can form speciﬁc complex with the p53 pro-
tein (Fig. 4). It should be noted that most of the known p53REs are
not composed of identical decamers. Typically, only one decamer
(halfsite) stringently adheres to the consensus, whereas the other
decamer(s) deviate from the consensus to a varying extent [15].
In this study, the p53-mediated induction of endogenous RIG1
mRNA and protein expression was demonstrated in cells treated
with 5-FU (in HepG2 cells) or transfected with inducible p53
expression vector (in H24-H1299 cells). Our observation suggested
that the induced expression of RIG1 might be associated with acti-
vation of p53 in cellular response to DNA damage or cytotoxic
drugs as elicited by 5-FU or UV light.
Having shown that p53 enhanced RIG1 expression, it is worthy
to note the functional implications of the p53-dependent expres-
sion of the RIG1 gene. p53 plays a central role in cellular processes
including cell cycle arrest and apoptosis. Deletion or mutations inthe p53 gene paves the way to tumorigenesis. The RIG1 is down-
regulated in many tumors and malignant cell lines. Forced expres-
sion of RIG1 has been shown to suppress ERK (extracellular signal-
regulated kinase), JNK (Jun N-terminal kinase), and p38MAPK
(mitogen-activated protein kinase) signaling pathways and subse-
quently inhibits cell growth, differentiation, and apoptosis [20,21].
A balance between the p53 and MAPK pathways appears to be crit-
ical for preventing or promoting initiation of tumors. By establish-
ing a direct link between p53 and transcriptional activation of the
RIG1 gene, our results suggest that p53 might negatively regulate
cell growth by induction of RIG1 expression and subsequently
deactivated the MAPK pathways. In fact, several p53 transcrip-
tional targets have been shown to deactivate MAPK pathways
when p53 response is activated by stress signals. Among them
are protein phosphatase Wip-1 and some dual-speciﬁcity phospha-
tases (DUSPs), including DUSP5/HVH3, DUSP2/PAC1, and MKP1
[22–24]. Upon p53 activation in response to various stimuli or
stresses, speciﬁc phosphatases are induced which in turn deacti-
vate MAP kinases and negatively regulate cell cycle progression.
Fig. 4. Direct binding of p53 to the rig-p53RE. (A) Probe and competitor DNA fragments used in EMSA. Gray box hightlights the p53RE and the asterisk (*) indicates that the
fragments was used as 32P-labeled probes. (B) Speciﬁc interaction of p53 with rig-p53RE. HepG2 cells were pretreated with 5-FU (10 lg/mL) for 48 h. The 32P-labeled probe
(20 fmol), rig 5175/5129, was incubated with 10 lg of HepG2 nuclear extract in the presence of the p53-speciﬁc monoclonal antibody PAb421. Speciﬁc binding (lane 2)
was competed by unlabeled RIG1 promoter fragments as indicated (lanes 3–10), or p21-p53RE (lane 11, 50-TACAGAACATGTCTAAGCATGCTGGGGACT-30), or RIG1 promoter
fragment with mutated p53RE (rig-mp53RE, lane 12). (C) Speciﬁc interaction of p53 with p21-p53RE is competed by rig-p53RE. EMSA experiment was performed using 32P-
labeled p21-p53RE (lanes 13–18) or rig-mp53RE (lanes 19–20). Unlabeled DNA fragments were added to at 100-fold molar excess as indicated. (D) ChIP analysis of p53
binding to the RIG1 promoter in HepG2 cells. Antibodies speciﬁc to p53, mouse IgG (negative control) were used for ChIP analysis of the RIG1 promoter under control and 5-
FU-treated (24 h, 10 lg/mL) conditions in HepG2 cells. The p53 binding site in the p21 promoter and a region containing no p53 binding sites in the GAPDH promoter serve as
positive and negative controls, respectively. (E) ChIP analysis of p53 binding to the RIG1 promoter in H24-H1299 cells. The H24-H1299 cells were incubated for 48 h in the
absence (p53 induced) or presence of 2 mg of tetracycline per mL.
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cept that the main role of p53 is to suppress cell growth and induce
apoptosis. This study also suggests an alternative mechanism by
which p53 downregulates the MAPK signaling pathways partly
through the induction of RIG1 gene expression. A scheme isproposed in Fig. 5 to depict the functional role of RIG1 in p53-med-
iated growth arrest.
In conclusion, we demonstrated that the expression of class II
tumor suppressor gene RIG1, is enhanced by the presence of p53
through a well-conserved p53RE in its upstream genomic region.
Fig. 5. p53 downregulates the MAPK signaling pathways partly through the
induction of RIG1 gene expression.
T.-H. Hsu et al. / FEBS Letters 586 (2012) 1287–1293 1293Our results indicated that RIG1 gene is a downstream target of p53
in cancer cell lines, which suggests a potential role of RIG1 in the
p53 deactivated MAPK pathways.
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